Amgen: slight decline in Q1 EPS
The biotech group saw its product sales rise by 25% in volume terms, boosted by growth of at least 10% for ten products, including Repatha, Tezspire, Evenity, Blincyto and Tavneos.
Amgen now expects adjusted EPS of between $19 and $20.20 and revenues of between $32.5 and $33.8 billion, compared with target ranges of $18.90-20.30 and $32.4-33.8 billion respectively previously.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction